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countries, range from $3,200-$18,000 per OA patient (excluding surgeries).
In addition, costs associated with side effects of currently available drugs
(e.g. NSAID-related serious GI event) were also found to be signiﬁcant.
Conclusions: Based on the ﬁndings of this literature review, the burden of
OA pain is signiﬁcant. There appears to be a great unmet need for new
innovative treatments that can signiﬁcantly reduce pain without the sides
effects associated with currently available treatment options and/or drugs
which may delay progression of disease.
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DEEP SEQUENCING OF GDF5 IN OVER 1900 OSTEOARTHRITIS CASES AND
CONTROLS REVEALS NOVEL AND POTENTIALLY FUNCTIONAL RARE
VARIANTS IN THE PROTEIN CODING AND PROMOTER REGIONS OF THE
GENE
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Purpose: We have assessed whether rare DNA variants in a gene already
known to be associated with knee and hip osteoarthritis (OA) contribute
to OA susceptibility. The selected gene is GDF5 (growth and differentiation
factor 5), which harbours a single nucleotide polymorphism, rs143383,
in its 5’ untranslated region that shows very robust association to OA in
European and Asian populations. The risk allele of this SNP mediates a small
decrease in GDF5 expression. These results indicate that polymorphism in
this gene of small singular impact are important for OA development and
suggest that rarer but more disruptive variants may have greater effects on
gene function and therefore OA susceptibility.
Methods: Three groups of patients and controls were studied from the
UK, Spain and Greece. There were 992 patients (502 British, 264 Spanish
and 226 Greek) that had each undergone a total knee or a total hip joint
replacement due to severe primary OA and 944 controls (460 British, 294
Spanish and 190 Greek). In the Spanish and Greek cohorts the search for
rare variants focussed on the two exons of GDF5 and was performed by
Sanger sequencing after PCR ampliﬁcation. The Polyphred software was
then used to align sequences and to identify DNA changes. The UK search
encompassed the two exons as well as both untranslated regions and
100bp of the proximal promoter of the gene. Sanger sequencing after PCR
ampliﬁcation was also performed, with the SeqScape software used to
identify DNA changes.
Results: In the UK cohort we discovered ﬁve novel rare variants in GDF5,
four in control individuals and one in a case. One of the variants, identiﬁed
in a control, is located 40 base pairs upstream of the transcriptional
start site and is predicted to interfere with a highly conserved SOX9
transcription factor binding site. Three of the remaining variants were
found in exon 2, all in control individuals, one of which is predicted to
cause a non-conservative substitution of a highly conserved threonine to
an arginine. The ﬁnal variant was a synonymous substitution in exon 1
detected in a female patient with knee OA. Only a synonymous substitution
was discovered in the Spanish or Greek samples, in a control individual.
Conclusions: Our deep-sequencing analysis of over 1900 OA cases and
controls from northern and southern Europe has identiﬁed several novel
rare variants in the OA-associated gene GDF5. The effects of these variants
upon GDF5 expression and protein structure will now be investigated using
luciferase assays, in-vitro splicing studies and protein modeling to discover
whether these alleles are potentially protective, harmful or neutral to OA
susceptibility.
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Purpose: Several lines of evidence suggest that estrogens inﬂuence the
development of osteoarthritis (OA). The aim of this study was to explore
the genetic and functional association of two common polymorphisms from
within the aromatase (CYP19A1) and estrogen receptor α (ESR1) genes with
severe OA of the lower limbs.
Methods: The rs1062033 (CYP19A1) and rs2234693 (ESR1) single nu-
cleotide polymorphisms (SNPs) were genotyped in 5,479 individuals (3,098
patients with hip or knee OA ascertained by the need for joint replacement
surgery due to severe primary OA, and 2,381 controls) from three centres
in Spain and one centre in the UK. Expression of CYP19A1 and ESR1
was measured in femoral bone RNA samples from a group of patients
by real-time quantitative PCR and was subsequently stratiﬁed by donor
genotype at rs1062033 and rs2234693.
Results: In the global analysis, both polymorphisms were associated with
OA, but there was a signiﬁcant sex interaction. The GG genotype at
rs1062033 (a C/G transversion SNP) was associated with an increased risk
of knee OA in women (OR 1.23; p=0.04). The CC genotype at rs2234693
(a C/T transition SNP) tended to be associated with reduced OA risk in
women (OR 0.76, p=0.028, for knee OA; OR=0.84, p=0.076 for hip OA), but
with increased risk of hip OA in men (OR 1.28; p=0.029). Women carrying
two copies of the rs1062033 G-allele and no copies of the rs2234693
C-allele were at particular risk for knee OA, with an OR of 1.61 (p=0.006).
The rs1062033 GG genotype associated with increased OA risk was also
associated with reduced expression of CYP19A1 in bone (p=0.036).
Conclusions: Common genetic variations of the aromatase and estrogen re-
ceptor α genes CYP19A1 and ESR1 are associated with the risk of severe OA
of the large joints of the lower limb in a sex-speciﬁc manner. These results
are consistent with the hypothesis that estrogen activity inﬂuences the
development of large-joint OA. The CYP19A1 SNP rs1062033, or a SNP in
linkage disequilibrium with it, may mediate its effect on OA susceptibility
by regulating the expression of CYP19A1.
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Purpose: Chronic Widespread Pain (CWP) is prevalent in approximately
10% of the general population and may result from inadequately treated
chronic focal pain problems such as osteoarthritis (OA) and inﬂuences
human well-being. The prognosis of CWP patients appears to be poor and
it is associated with increased consumption of health care and working
disability. CWP is regarded to be a complex trait, meaning that both
environmental and genetic factors play a role in the etiology. Twins studies
have estimated a heritability of 48-54% for CWP. So far candidate gene
studies have not been able to discover genes involved in the pathogenesis
of CWP, possibly due to small sample sizes. Meta-analysis of Genome Wide
Association Studies (GWAS) from several population based cohort studies
is a hypothesis-free and more robust state-of-the-art approach to identify
genetic risk factors. The objective of this study was to identify genes
involved in CWP by means of a large-scale GWAS meta-analysis.
Methods: CWP is deﬁned as pain present in at least both sides of the
body, pain above and below the waist, and axial skeletal pain (the FMS
criteria of the American College of Rheumatology (ACR)). We conducted
S166 Poster Presentations / Osteoarthritis and Cartilage 18, Supplement 2 (2010) S45–S256
a meta-analysis of GWAS with > 2,500,000 imputed SNPs in Caucasian
women from four population-based cohorts: three cohorts from the Rotter-
dam Study (RS-I, RS-II, and RS-III) and the Erasmus Rucphen Family (ERF)
Study. Controls using analgesics were excluded. In total approximately 680
cases and 4180 controls were included in the meta-analysis. The program
METAL was used to perform the meta-analysis using an additive model. The
genomic control method was used to correct for any residual population
stratiﬁcation or relatedness not accounted for by the four most important
PCs (all lambda’s < 1.1).
Results: The average prevalence of CWP in the four studies was 15%. The
most signiﬁcant signal of the meta-analysis was at 4p15.3, in intron 1 of
Prominin 1 (PROM1), which reached borderline genome wide signiﬁcance
(p=5.5×10-8). The effect allele T (minor allele frequency = 6%) of the
most signiﬁcant SNP gives a consistent higher risk for CWP in all four
cohorts examined (meta-analysis OR per T-allele: 1.74, 95% CI: 1.43-2.14,
p=5.5×10-8). As observed from RS-I data, the effect allele also gives a
higher risk for joint speciﬁc pain in hip (p = 0.024, OR: 1.34, 95% CI:
1.03-1.71), hand (p=0.021, OR: 1.31, 95% CI: 1.04-1.65), and low back and
neck (p=0.001, OR: 1.43, 95% CI: 1.16-1.76). The PROM1 gene encodes a
pentaspan transmembrane glycoprotein, for which no link with CWP has
been established yet.
Conclusions: This large GWAS meta-analysis on CWP shows a strongly
suggestive association for CWP in women at chr4p15.3, just escap-
ing genome-wide signiﬁcance. Therefore, replication in other cohorts is
needed, which might unveil further loci for CWP.
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Purpose: To clarify the role of common genetic variation in the Interleukin-
1β (IL1B) and Interleukin-1R antagonist (IL1RN) genes on risk of prevalence
of knee and hip osteoarthritis (OA) and severity of knee OA by means of
large-scale meta-analyses.
Methods: We searched PubMed for articles assessing the role of IL1B and
IL1RN polymorphisms and haplotypes on the risk of hip and/or knee OA.
Novel data was included from 8 additional studies. A meta-analysis was
performed using ﬁxed- and random-effects models, including all available
data with allele/genotype counts, with a total of 3676 hip OA and 5128
knee OA cases, and 6559 and 9132 controls respectively. The role of ILRN
haplotypes on radiographic severity of knee OA, previously reported, was
tested in 1918 cases with Kellgren-Lawrence (K/L) 1 or 2 compared to 199
cases with K/L 3 or 4.
Results: The meta-analysis showed no evidence of association between
common genetic variation in the IL1B or IL1RN genes and risk of hip
OA or knee OA (P>0.05 for rs16944, rs1143634, rs419598 and haplotype
C-G-C (rs1143634, rs16944 and rs419598) previously implicated in risk of
hip OA). The C-T-A haplotype formed by rs419598, rs315952 and rs9005,
previously implicated in radiographic severity of knee OA, was associated
with reduced severity of knee OA (OR=0.71 95%CI 0.56-0.91; P=0.006,
I2=74%), but did not achieve statistical signiﬁcance in a random effects
model (OR=0.61 95%CI 0.35-1.06 P=0.08).
Conclusions: Common genetic variation in the Interleukin-1 region is not
associated with prevalence of hip or knee OA but may be associated with
severity of knee OA.
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Purpose: Osteoarthritis (OA), the most common form of arthritis, is a mul-
tifactorial disease thought to be caused by complex interplay between envi-
ronmental and genetic factors. The genetic architecture of OA has not been
characterised yet; as with many common complex traits it appears to be
of a highly polygenic nature with multiple risk loci conferring small effects,
detection of which necessitates studies in sets of large sample sizes. In order
to enable a well-powered genome-wide association study (GWAS) for OA,
we have formed the arcOGEN Consortium, a UK-wide collaboration aiming
to carry out a genome-wide scan of 8,000 OA cases in a 2-stage GWAS.
Methods: We have completed stage 1 GWAS in 3,177 knee and/or hip OA
cases, genotyped on the Illumina Human610 chip and have compared their
genotypes against 4,894 publicly available population-based UK controls
from the Wellcome Trust Case Control Consortium 2 (WTCCC2) study,
genotyped on the Illumina 1.2M platform.
Results: Of the 514,898 single nucleotide polymorphisms (SNPs) that
passed our quality control, 90 SNPs reached p values < 0.0001 (as op-
posed to 51 expected under the null hypothesis of no association). We
took forward 102 independent (r2<0.4) SNPs with p<0.0001 to in silico
replication in three further OA GWAS (from the deCODE, Framingham and
Rotterdam studies) and a subset of 52 SNPs in a UK-based GWAS (Twins
UK) comprising a total of 41,075 individuals. Based on meta-analysis results
across the arcOGEN and in silico replication datasets we prioritised 36 SNPs
for de novo replication in a further set of 6,255 OA cases and 8,289 controls
of European ancestry (from Spain, Greece, USA and the Netherlands). None
of the followed-up signals reached genome-wide signiﬁcance (p<5×10-8),
but this could be due to low power caused by limited sample size, small
effect sizes and phenotype heterogeneity. In the knee and/or hip OA
meta-analysis across the discovery and replication sets, the strongest signal
was observed for rs2277831, which lies within the MICAL3 gene (odds
ratio for the G allele (OR) 1.07 [1.04-1.11], p=2.85×10-5). We also examined
